PLIANT THERAPEUTICS INC
For the period ended Mar 31, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 6, 2024
PLRX$0.79-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| (In thousands) | 2024 | 2023 |
| Cash flows from operating activities | ||
| Net loss | $(46,955) | $(37,548) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 513 | 452 |
| Stock-based compensation expense | 9,666 | 11,923 |
| Non-cash operating lease expense | 681 | 609 |
| Net amortization (accretion) on short-term investments and debt | 1,091 | (2,584) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | (1,314) |
| Prepaid expenses and other current assets | 3,749 | (476) |
| Accounts payable | 2,257 | (144) |
| Accrued liabilities | (910) | (538) |
| Operating lease liabilities | (363) | (656) |
| Net cash used in operating activities | (30,271) | (30,276) |
| Cash flows from investing activities | ||
| Purchase of short-term investments | (52,375) | (276,620) |
| Maturity of short-term investments | 113,413 | 102,575 |
| Purchase of property and equipment | (1,492) | (163) |
| Net cash used in (provided by) investing activities | 59,546 | (174,208) |
| Cash flows from financing activities | ||
| Proceeds from issuances of common stock under benefit plans | 1,879 | 3,661 |
| Proceeds from term loan, net | 19,909 | — |
| Payment of offering costs | — | (586) |
| Proceeds from sale of common stock in a public offering | — | 270,251 |
| Net cash provided by financing activities | 21,788 | 273,326 |
| Net increase in cash and cash equivalents | 51,063 | 68,842 |
| Cash and cash equivalents and restricted cash at beginning of period | 64,716 | 33,685 |
| Cash, cash equivalents and restricted cash at end of period | $115,779 | $102,527 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid for interest | $501 | $282 |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets | ||
| Cash and cash equivalents | $114,297 | $102,527 |
| Restricted cash | 1,482 | — |
| Total cash, cash equivalents, and restricted cash shown in the statements of cash flows | $115,779 | $102,527 |
| Supplemental disclosures of noncash investing and financing activities: | ||
| Net unrealized (loss) gain on short-term investments | $(834) | $636 |
| Purchase of property and equipment in accounts payable and accrued liabilities | $1,059 | $— |
| Supplemental disclosures of cash flow information related to leases: | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $23,698 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.